Skip to main content
Premium Trial:

Request an Annual Quote

Chanel? Vuitton? Avastin?


Roche's Genentech is warning oncologists that counterfeiters are making and selling fake Avastin in the US, reports the Associated Press' Matthew Perrone. Although it's unclear how many vials of the counterfeit drug have been distributed, a company spokeswoman said some have gone to healthcare facilities, Perrone adds. Although the company does not know what's actually in the vials of fake medicine, the spokeswoman added that they do not contain the ingredients that make Avastin an effective treatment for colon, lung, kidney, and brain cancer.

"In a related action, the FDA said late Tuesday it has contacted 19 medical practices that may have purchased unapproved drugs, including counterfeit Avastin, from a company called Quality Specialty Products," Perrone says. "The foreign supply company may also do business as Montana Health Care Solutions. ... Genentech was alerted to the problem by foreign health regulators and company officials believe the counterfeits were imported from abroad, though they could not specify which country."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.